Drug intelligence / Profile preview

SV001

Development stage: Phase 2
Lead developer: Shanghai Xunyao Biotechnology
Modality: Small Molecules
Administration: Inhalation

Overview

SV001 is an investigational drug currently being evaluated in a Phase 1 clinical trial as a nebulized inhalation solution. The study aims to assess the safety, tolerability, pharmacokinetics, and immunogenicity of SV001 in healthy adult volunteers. The trial is sponsored by Shanghai Xunyao Biotechnology and is being conducted in China. The precise mechanism of action and therapeutic target for SV001 have not been disclosed in publicly available sources[2][3].

Targets

PEAR1 (Platelet endothelial aggregation receptor 1)

Beyond the preview

Go deeper on SV001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SV001.

Explore the full profile